vimarsana.com

Page 29 - கல்லூரி ஆஃப் அமெரிக்கன் நோயியல் நிபுணர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Radiology and Radiation Oncology | Imaging Technology News

Methodology for evaluation of tumor cell density (TCD) and allocation of radiotherapy response categories. (A) Virtual graticule of approximately 300 points applied to tumor area on a digital H&E section. (B) Demonstration of TCD point scoring. (C) Box and whisker plot to show the relationship between ΔTCD and American Joint Committee on Cancer (AJCC) Tumour Regression Grade System (TRG). (D, E) Allocation of three radiotherapy response groups according to change in TCD (ΔTCD) for short-course radiotherapy (SCRT) (D) and long-course chemoradiotherapy (LCRT) (E). The Kruskall-Wallis test was used for statistical comparisons. Image courtesy of BMJ

Nasdaq Grants Bionano Genomics 180-Day Extension to Regain Compliance

Posted on 4448 Bionano Genomics, Inc. (NASDAQ: BNGO)reported that Nasdaq granted the company an extra 180-day compliance period which will end on June 28th, 2021 to regain compliance with Nasdaq’s minimum USD 1.00 closing bid price per share requirement.  All other requirements have been met.  Erik Holmlin, PhD, CEO of Bionano Genomics commented: “We are pleased that Nasdaq granted our request for an extension. We have been making steady progress with our business and this extension gives us extra time to regain compliance as we continue to advance the Saphyr System in our target markets of discovery research and Cytogenomics.” The company also recently announced that Praxis Genomics, LLC received recognition from the College of American Pathologists.  This makes it the first CAP-accredited CLIA certified diagnostic lab within the U.S. to offer a laboratory developed tests based on whole genome analysis with S

Sterling Pathology National Laboratories Launches Automated COVID-19 Testing Platform Capable of an Additional 7,000 Tests per Day to Strengthen National Response to Pandemic

Share this article Share this article SEAL BEACH, Calif., Dec. 23, 2020 /PRNewswire/   Sterling Pathology National Laboratories announced the launch of MGITSP-7000 and MGI SP-960, CLIA-certified COVID-19 automated equipment capable of high-throughput of sample preparation. The MGITSP-7000 and MGI SP-960 are fully automated workstations featuring a 96-channel pipette, fully automatic operation design, realize walk-away process capability, and can be customized according to user needs. It is an efficient and widely used automated sample preparation system. Sterling Pathology, based in Seal Beach, CA, will begin processing clinical COVID-19 samples to support public health efforts over the coming weeks, with a near-term goal of performing an additional 7,000 tests per day to our current run of 500-1,000 tests per day, with a laboratory turnaround time of 24 hours.

The Battle to Patent Your Genes - The American Interest

https://www.the-american-interest.com/2009/09/01/the-battle-to-patent-your-genes/ The American Interest A legal showdown looms over the corporations that want to own our DNA. April 12, 1955 was a day of celebration. Across the United States, church bells rang, sirens blew, and people poured into the streets singing and dancing. The rejoicing was a spontaneous response to news that field trials of Jonas Salk’s vaccine against the dread polio virus had been successful. The public had avidly followed the search for a vaccine for years. Hundreds of thousands of volunteers had participated in the trials, and tens of millions contributed dimes, quarters and dollars to the effort. According to a 1954 Gallup poll, more Americans knew about the polio field trials than knew the full name of their President, Dwight David Eisenhower.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.